RET Inhibitors in Non-Small-Cell Lung Cancer

RET Inhibitors in Non-Small-Cell Lung Cancer

RET rearrangements are observed in 1–2% of non-small-cell lung cancer (NSCLC) patients and result in the constitutive activation of downstream pathways normally implied in cell proliferation, growth, differentiation and survival. In NSCLC patients, RET rearrangements have been associated with a hist...

Full description

Bibliographic Details
Main Authors: Priscilla Cascetta, Vincenzo Sforza, Anna Manzo, Guido Carillio, Giuliano Palumbo, Giovanna Esposito, Agnese Montanino, Raffaele Costanzo, Claudia Sandomenico, Rossella De Cecio, Maria Carmela Piccirillo, Carmine La Manna, Giuseppe Totaro, Paolo Muto, Carmine Picone, Roberto Bianco, Nicola Normanno, Alessandro Morabito
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
NSCLC
RET
selpercatinib
pralsetinib
cabozantinib
vandetanib
Online Access:https://www.mdpi.com/2072-6694/13/17/4415

Internet

https://www.mdpi.com/2072-6694/13/17/4415

Similar Items